Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1043 participants.
Also called NCT02052310
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,043 participants
- Registry
-
NCT02052310 -
2013-002753-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Bulgaria, Chile, Colombia, Latvia, Malaysia, Mexico, Poland, Romania, Russia, South Korea, Taiwan, Thailand, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02052310. Randomized; no masking; primary purpose treatment. Start 2014-02-11 (actual); primary completion 2018-09-21 (actual). Results posted on 2021-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
- Acronym
- Himalayas
- Condition
- Anemia in Incident Dialysis Patients
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Epoetin Alfa
- Lead sponsor
- Kyntra Bio
- Collaborator
- Astellas Pharma Europe B.V.
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02052310- Content hash
360fc8780ebb864584070a5f2a9c79738090ac8355a9652218da667ecc61b481